Lauren Fishbein

List of Publications by Year
in descending order

35 papers	2,180 citations	471509 17 h-index	395702 33 g-index
35 all docs	35 docs citations	35 times ranked	3397 citing authors

#	Article	IF	Citations
1	Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1159-1169.	3.6	7
2	Case of Metastatic Pheochromocytoma and Meningiomas in a Patient With Lynch Syndrome. JCO Precision Oncology, 2022, 6, e2100251.	3.0	1
3	SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas. Cell Reports, 2022, 38, 110453.	6.4	16
4	Head and Neck Paragangliomas: An Update on the Molecular Classification, State-of-the-Art Imaging, and Management Recommendations. Radiology Imaging Cancer, 2022, 4, e210088.	1.6	17
5	Impact of COVID-19 on individuals with paraganglioma/pheochromocytoma history and/or hereditary risk.. Journal of Clinical Oncology, 2022, 40, 10613-10613.	1.6	0
6	Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e350-e364.	3.6	8
7	Genetics of pheochromocytoma and paraganglioma. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 283-290.	2.3	22
8	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas, 2021, 50, 469-493.	1.1	55
9	Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression. Molecular Cancer Research, 2021, 19, 1476-1485.	3.4	11
10	Correlation Between Plasma Catecholamines, Weight, and Diabetes in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4028-e4038.	3.6	13
11	Targeted genomic analysis of 364 adrenocortical carcinomas. Endocrine-Related Cancer, 2021, 28, 671-681.	3.1	13
12	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas, 2020, 49, 863-881.	1.1	88
13	Tumor detection rates in screening of individuals with SDHx-related hereditary paragangliomaâ€“pheochromocytoma syndrome. Genetics in Medicine, 2020, 22, 2101-2107.	2.4	20
14	Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4661-e4670.	3.6	40
15	The Changing Paradigm of Head and Neck Paragangliomas: What Every Otolaryngologist Needs to Know. Annals of Otology, Rhinology and Laryngology, 2020, 129, 1135-1143.	1.1	20
16	Case report of a paraganglioma arising from a mature cystic teratoma of the ovary. Gynecologic Oncology Reports, 2020, 32, 100537.	0.6	3
17	Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. Cancers, 2019, 11, 1121.	3.7	36
18	Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?. Current Cardiology Reports, 2019, 21, 104.	2.9	16

#	Article	IF	Citations
19	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clinical Cancer Research, 2018, 24, 3059-3068.	7.0	366
20	Chromaffin cell biology: inferences from The Cancer Genome Atlas. Cell and Tissue Research, 2018, 372, 339-346.	2.9	17
21	Development of new preclinical models to advance adrenocortical carcinoma research. Endocrine-Related Cancer, 2018, 25, 437-451.	3.1	45
22	Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. Endocrinology, 2018, 159, 2532-2544.	2.8	19
23	Discovery of new susceptibility genes: proceed cautiously. Genetics in Medicine, 2018, 20, 1512-1514.	2.4	3
24	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532
25	Pheochromocytoma and Paraganglioma Susceptibility Genes. JAMA Oncology, 2017, 3, 1212.	7.1	4
26	The Jewel in the Crown: Specific Aims Section of Investigator-Initiated Grant Proposals. Journal of the Endocrine Society, 2017, 1, 1194-1202.	0.2	8
27	Pheochromocytoma and Paraganglioma. Hematology/Oncology Clinics of North America, 2016, 30, 135-150.	2.2	127
28	Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. JCI Insight, 2016, 1, e88207.	5.0	38
29	Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget, 2016, 7, 48577-48585.	1.8	6
30	Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6140.	12.8	143
31	Inherited Mutations in Pheochromocytoma and Paraganglioma: Why All Patients Should Be Offered Genetic Testing. Annals of Surgical Oncology, 2013, 20, 1444-1450.	1.5	182
32	Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma. Journal of Clinical Hypertension, 2013, 15, 428-434.	2.0	62
33	Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genetics, 2012, 205, 1-11.	0.4	177
34	In vitro studies of steroid hormones in neurofibromatosis 1 tumors and schwann cells. Molecular Carcinogenesis, 2007, 46, 512-523.	2.7	39
35	Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. Cancer Genetics and Cytogenetics, 2005, 157, 181-186.	1.0	26